High-quality viral reference reagents were developed for the U.S. Food and Drug Administration’s (FDA) Division of Viral Products (DVP) within the Center for Biologics Evaluation and Research (CBER) to evaluate the sensitivity of next-generation sequencing (NGS) platforms, enable the optimization of metagenomics workflows, and provide reliable comparative data while improving assay consistency by multiple groups. ATCC was awarded a contract from FDA CBER to support these collaborative studies through the production of large quantities of purified, well-characterized virus stocks that are used as standards for NGS platforms evaluating the presence of adventitious viruses.